{"paper_id":"e85f61ef-1b09-43c8-b0b3-af37fa648e61","body_text":"Endometriosis is a common but understudied disease, affecting around 10% of reproductive-age women. The true prevalence of the disease in the general population is likely underestimated as some women are asymptomatic and when symptoms do exist, they tend to be variable and nonspecific  [1] . Clinical presentation of patients with suspected endometriosis includes dysmenorrhea, dyspareunia, chronic pain and infertility, often accompanied by gastrointestinal, urinary and systemic symptoms. Additionally, certain endometriosis subtypes are associated with increased risk of ovarian cancer  [2] ,  [3] .\nThe gold-standard for endometriosis diagnosis is histologically-confirmed observations of endometrial-type cells with or without endometrial-type glands present within surgically excised specimens  [4] ,  [5] . However, in a subset of patients presenting with a pattern of symptoms strongly suggestive of endometriosis, lesions cannot be detected by surgical visualization nor histopathologic examination of excised tissue  [6] ,  [7] . Data are lacking regarding the characteristics and comorbidities in this distinct subgroup, defined in our study as “clinically suspected endometriosis with negative pathology” (CSENP). Pain and depression may co-exist through shared biological pathways, described as a depression-pain dyad  [8]  and patients with confirmed endometriosis report higher rates of anxiety and/or depression  [9] ,  [10] ,  [11] . However, the burden of these comorbidities in CSENP patients is not well documented.\nRecent studies highlight the increasing prevalence of cannabis use for management of pelvic pain, both related and unrelated to endometriosis  [12] ,  [13] . Currently, data are insufficient to make an official recommendation regarding the use of cannabis products for pain control or mental health management  [14] ,  [15] . The objective of this study is to determine the association of CSENP and diagnoses of anxiety, depression, and pain with a focus on the use of cannabinoid-containing products.\n\nIn this prospective cohort study, we recruited women ages 18–60 years who were scheduled for gynecological surgery in the Division of Minimally Invasive Gynecologic Surgery at Cedars-Sinai Medical Center between October 2019 and March 2024. Individuals undergoing surgery to address pelvic pain or suspicion for endometriosis, uterine fibroids, or other benign gynecological conditions were eligible for recruitment. Candidates were contacted by phone prior to surgery to obtain informed consent.\nParticipants were emailed a questionnaire after they consented to participate in the study adapted, in part, through the surveys developed by the World Endometriosis Research Foundation (WERF) Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) ( https://endometriosisfoundation.org/ephect/#ephect-sops-questionnaires-forms )  [16] ,  [17] . Questions were added to capture the use of cannabis and cannabidiol products (CBD)  [18] . Medical history, and surgical and pathological characteristics were extracted from the electronic medical records by study staff. Each participant’s record was reviewed by two team members and any differences in data collection were reviewed to reach a consensus. Clinical data and questionnaires were collected and recorded using a REDCap data base  [19] ,  [20] .\nBaseline and preoperative characteristics included age, body mass index, race, ethnicity, marital status, presence of autoimmune disease, and American Society of Anesthesiologists class.\nSelf-reported anxiety and depression included the questions: “Have you ever had any of the following medical conditions and if so, at what age you were first diagnosed by a doctor?”; “Anxiety requiring medication or therapy”; “Depression requiring medication or therapy”. Questions regarding the use of cannabis or CBD were as follows: “Have you used cannabis (marijuana) on 10 or more occasions in your lifetime?”; “Have you used CBD (cannabidiol) products on 10 or more occasions in your lifetime?”; “On average how often did you use cannabis (marijuana) in the past 12 months?” On average, how often did you use CBD products in the past 12 months?” “Which medical condition(s) do you use cannabis or CBD products for?”. The latter question included the options “pain”, “anxiety”, and “depression”.\nWe collected endometriosis stage for patients in the endometriosis with positive pathology group, based on the Revised American Society for Reproductive Medicine classification of endometriosis (ASRM) classification  [21] .\nSurgical specimens were retrieved in all cases. Among CSENP patients, peritoneal biopsies were obtained in all cases, with excised areas selected at the provider’s discretion. All surgically removed specimens were subjected to standard-of-care histopathologic examination. Endometriosis was diagnosed when endometrial-type epithelium and/or stromal cells with or without endometrial-type glands present when reviewed by a specialist gynecologic pathologist experienced in endometriosis identification.\nThe study cohort was stratified into three groups: 1. Endometriosis with positive pathology- patients with a positive histopathologic diagnosis of endometriosis on the current surgery; 2. No endometriosis- a control group consisting of patients with no perioperative suspicion of endometriosis, and a visually confirmed absence of endometriosis; 3. Clinically suspected endometriosis with negative pathology (CSENP)- patients where endometriosis was clinically suspected (based on symptoms), but histopathology was negative. Clinical criteria for a clinical suspicion of endometriosis included dysmenorrhea, dyspareunia, chronic pelvic pain, infertility, pelvic exam consistent with endometriosis.\nWe used univariate analysis to compare study groups. For categorical variables we used Chi-square test and Fisher’s exact test. Pairwise comparison of proportions using the Bonferroni correction we deployed to identify which pairs of groups were significantly different. For continuous variables we used the one-way Analysis of variance (ANOVA) test for multiple comparisons. Post hoc Tukey’s Honest Significant Difference test was then used to identify which pairs of groups were significantly different. Categorical variables were reported as proportions and continuous variables as mean ± standard deviation. Multivariable logistic regression analyses were performed to examine the association of endometriosis suspected clinically with negative pathology with depression, anxiety and the combination of anxiety or depression, and the association of the use of cannabis with pain, anxiety, depression, and the combination of anxiety or depression. The multivariable logistic regression analysis models included factors that reached a statistically significant difference in the univariate analysis and are clinically relevant, including race, depression and anxiety. Results are reported as adjusted odds ratio (aOR) and 95% confidence interval (CI). A 2-sided p-value < .05 was considered statistically significant. Statistical analyses were performed using IBM SPSS version 27 (IBM Corp, Armonk, NY), EZR (version 1.55) and R software (Core Team, 2021, version 4.1.2).\n\nThis study was performed with the approval and oversight of the Cedars-Sinai Institutional Review Board (STUDY00000063). Patients received no financial compensation for participation.\n\nDuring the study period, 454 participants were recruited. 308 (67.8%) had a pathologically confirmed diagnosis of endometriosis, 101 (22.2%) had no evidence of endometriosis (controls), and 45 (9.9%) were diagnosed with CSENP ( Table 1 ). Women with histologically confirmed endometriosis and CSENP were younger than women with no endometriosis (35.6 and 34.8  versus  41.9 years, respectively, p < 0.001). BMI was lower among women with histologically confirmed endometriosis compared with women without endometriosis (25.6  versus  28.4 kg/m 2 , p < 0.001). Compared to controls, patients with endometriosis were less likely to be African American (p < 0.001). Table 1 Characteristics of patients included in the study. Endometriosis with positive pathology (n = 308) Endometriosis suspected clinically with negative pathology (n = 45) No endometriosis (n = 101) p value Age 35.6 ± 7.4 a 34.8 ± 10.1 a 41.9 ± 7.7 b <.001 Body mass index, kg/m 2 25.6 ± 5.7 a 26.9 ± 6.8 a,b 28.4 ± 6.0 b <.001 Race <.001 White 213 (69.2) a,b 37 (82.2) a 60 (59.4) b Black or African American 16 (5.2) a 3 (6.7) a,b 22 (21.8) b Asian 34 (11.0) a 1 (2.2) a 7 (6.9) a Native Hawaiian or Other Pacific Islander 0 (0.0) a 0 (0.0) a 1 (1.0) a American Indian or Alaska Native 4 (1.3) a 0 (0.0) a 1 (1.0) a Other/Multi-racial 41 (13.3) 4 (8.9) a 10 (9.9) a Hispanic ethnicity 54 (17.5) 5 (11.1) 17 (16.8) .303 Married or in a relationship 189 (61.4) 25 (55.6) 60 (59.4) .740 Autoimmune disease 38 (12.3) 7 (15.6) 11 (10.9) .731 ASA Class .397 1 114 (40.0) 12 (28.6) 27 (32.5) 2 153 (53.7) 26 (61.9) 52 (62.7) 3 18 (6.3) 4 (9.5) 4 (4.8) Anxiety requiring therapy or medication 163 (52.9) 27 (60.0) 47 (46.5) .292 Depression requiring therapy or medication 130 (42.2) 27 (60.0) 41 (40.6) .063 Anxiety or depression requiring therapy or medication 179 (58.1) 31 (68.9) 57 (56.4) .336 Cannabis use 207 (51.7) 29 (51.7) 59 (55.9) .844 Cannabis used for Pain 89 (28.9) a 10 (22.2) a,b 11 (10.9) b .001 Anxiety 47 (15.3) 9 (20.0) 7 (6.9) .050 Depression 19 (6.2) 3 (6.7) 4 (4.0) .681 CBD use 98 (46.4) 14 (50.0) 19 (31.7) .099 CBD used for Pain 81 (26.3) a 9 (20.0) a,b 11 (10.9) b .005 Anxiety 47 (15.3) 9 (20.0) 7 (6.9) .050 Depression 19 (6.2) 3 (6.7) 4 (4.0) .681 Data are n (%) or mean ± standard deviation. ASA: American Society of Anesthesiologists. A superscript letter different than the superscript letter in another group denotes statistically significant difference (p < .05). Identical superscript letter in two groups denotes lack of statistical difference.\nCharacteristics of patients included in the study.\nData are n (%) or mean ± standard deviation. ASA: American Society of Anesthesiologists.\nA superscript letter different than the superscript letter in another group denotes statistically significant difference (p < .05). Identical superscript letter in two groups denotes lack of statistical difference.\nThere were no significant differences between groups in the proportion of anxiety (p = 0.292) or depression (p = 0.063). Similarly, groups were comparable in the proportion of cannabis and CBD use (p = 0.844 and p = 0.099, respectively). However, when stratified by reason for cannabis use, more women with endometriosis used it for pain compared with control (28.9% vs. 10.9%, respectively, p = 0.001). Similarly, CBD was used more often for pain among endometriosis patients compared with controls (26.3% vs. 10.9%, respectively, p = .005) and marginally more women with endometriosis and CSENP used cannabis for anxiety compared with control (20.0% vs. 6.9%, respectively, p = 0.050).\nPain characteristics are presented in  Table 2 . The proportions of dysmenorrhea in all periods, dyspareunia and painful bladder syndrome were higher in the endometriosis and CSENP groups compared to control (p < 0.001). Table 2 Pain characteristics. Endometriosis with positive pathology (n = 293) Endometriosis suspected clinically with negative pathology (n = 40) No endometriosis (n = 87) P-value Dysmenorrhea <.001 - Mild cramps (medication never or rarely needed) 20 (6.5) a 2 (4.4) a,b 18 (17.8) b - Moderate cramps (medication usually needed) 51 (16.6) a 12 (26.7) a,b 30 (29.7) b - Severe cramps (medication and bed rest needed) 222 (72.1) a 26 (57.8) a,b 39 (38.6) b How often do you experience dysmenorrhea <.001 - Occasionally (less than a quarter of my periods) 20 (6.5) a 2 (4.4) a 25 (24.8) b - Often (a quarter to half of my periods) 19 (6.2) a 7 (15.6) a,b 15 (14.9) b - Usually (more than half of my periods) 49 (15.9) a 8 (17.8) a 20 (19.8) a - Always (every period) 212 (68.8) a 26 (57.8) a 34 (33.7) b Dyspareunia 224 (72.7) a 30 (66.7) a 42 (41.6) b <.001 Non-cyclic pelvic pain 209 (67.9) a 31 (68.9) a,b 51 (50.5) b .005 Medications for non-cyclic pelvic pain 154 (88.0) 24 (88.9) 29 (74.4) .077 Age non-cyclic pain started 26.04 (9.43) 25.69 (8.92) 29.33 (12.03) .122 Painful bladder syndrome 28 (9.1) a 6 (13.3) a 1 (1.0) b .010 Data are n (%) or mean ± standard deviation\nPain characteristics.\nMild cramps (medication never or rarely needed)\nModerate cramps (medication usually needed)\nSevere cramps (medication and bed rest needed)\nOccasionally (less than a quarter of my periods)\nOften (a quarter to half of my periods)\nUsually (more than half of my periods)\nAlways (every period)\nData are n (%) or mean ± standard deviation\nSurgical characteristics are presented in  Table 3 . Compared with controls, women with endometriosis underwent fewer hysterectomies (22.7%  versus  48.5%, respectively, p < .001). Women with endometriosis and CSENP underwent fewer myomectomies compared with controls (24.7% and 13.3%  versus  46.5%, respectively, p < 0.001). Among women with endometriosis, the proportion of stage 3 or 4 endometriosis was 39.3%. Table 3 Surgical characteristics. Endometriosis with positive pathology (n = 308) Endometriosis suspected clinically with negative pathology (n = 45) No endometriosis (n = 101) p value Hysterectomy 70 (22.7) a 17 (37.8) a,b 49 (48.5) b <.001 Myomectomy 76 (24.7) a 6 (13.3) a 47 (46.5) b <.001 Endometrioma excised 87 (28.2) - - NA Endometriosis stage - - NA 1 112 (36.4) 2 75 (24.4) 3 36 (11.7) 4 85 (27.6) Endometriosis stage 3/4 121 (39.3) - - NA Data are n (%) A superscript letter different than the superscript letter in another group denotes statistically significant difference (p < .05). Identical superscript letter in two groups denotes lack of statistical difference.\nSurgical characteristics.\nData are n (%)\nA superscript letter different than the superscript letter in another group denotes statistically significant difference (p < .05). Identical superscript letter in two groups denotes lack of statistical difference.\nMultivariable regression analysis of the association of study groups and anxiety and depression is presented in  Table 4 . After adjustment, there were no significant differences between groups in risk of anxiety or the combination of anxiety and depression. However, when analyzing depression, CSENP patients had higher risk of depression compared with patients with endometriosis (aOR 2.27, 95% CI 1.03–5.03). When adjusted for pain characteristics, results remained unchanged. Table 4 Multivariable regression analysis of the association between endometriosis status and anxiety and depression. Adjusted Odds Ratio (95% Confidence Interval) p value Anxiety * Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 0.74 (0.33–1.65) .465 Endometriosis not suspected and not diagnosed 0.70 (0.39–1.24) .219 Depression ** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 2.27 (1.03–5.03) .043 Endometriosis not suspected and not diagnosed 1.18 (0.66–2.11) .574 Anxiety or depression *** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.42 (0.72–2.81) .309 Endometriosis not suspected and not diagnosed 0.95 (0.59–1.53) .838 * Adjusted for race and depression requiring therapy or medications ** Adjusted for race and anxiety requiring therapy or medications *** Adjusted for race\nMultivariable regression analysis of the association between endometriosis status and anxiety and depression.\nAdjusted for race and depression requiring therapy or medications\nAdjusted for race and anxiety requiring therapy or medications\nAdjusted for race\nMultivariable regression analysis of the association of study groups and use of cannabis is presented in  Table 5 . Compared with women with endometriosis, controls were less likely to use cannabis for pain (aOR 0.32, 95% CI 0.16–0.64). No differences between groups were found in the use of cannabis for anxiety or the combination of anxiety and depression. Compared with patients with endometriosis, CSENP patients were more likely to use cannabis for depression (aOR 1.92, 95% CI 1.01–3.65). Table 5 Multivariable regression analysis of factors associated with use of cannabis. Adjusted Odds Ratio (95% Confidence Interval) p value Cannabis for Pain * Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 0.62 (0.29–1.32) .216 Endometriosis not suspected and not diagnosed 0.32 (0.16–0.64) .001 Cannabis for Anxiety ** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.16 (0.52–2.62) .714 Endometriosis not suspected and not diagnosed 0.49 (0.21–1.14) .099 Cannabis for Depression *** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.92 (1.01–3.65) .047 Endometriosis not suspected and not diagnosed 0.96 (0.60–1.54) .865 Cannabis for Anxiety or depression** * Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.42 (0.72–2.81) .309 Endometriosis not suspected and not diagnosed 0.95 (0.59–1.53) .838 * Adjusted for race, anxiety, depression ** Adjusted for race, depression *** Adjusted for race\nMultivariable regression analysis of factors associated with use of cannabis.\nAdjusted for race, anxiety, depression\nAdjusted for race, depression\nAdjusted for race\nMultivariable regression analysis of the association of study groups and use of CBD is presented in  Table 6 . Compared with women with endometriosis, controls were less likely to use CBD for pain (aOR 0.36, 95% CI 0.18–0.72). No differences between groups were found in the use of cannabis for anxiety, depression, or the combination of anxiety and depression. Table 6 Multivariable regression analysis of factors associated with use of CBD. Adjusted Odds Ratio (95% Confidence Interval) p value CBD for Pain * Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 0.62 (0.28–1.37) .237 Endometriosis not suspected and not diagnosed 0.36 (0.18–0.72) .004 CBD for Anxiety ** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.16 (0.52–2.62) .714 Endometriosis not suspected and not diagnosed 0.49 (0.21–1.14) .099 CBD for Depression *** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 0.99 (0.28–3.55) .988 Endometriosis not suspected and not diagnosed 0.68 (0.22–2.07) .498 CBD for Anxiety or depression **** Endometriosis with positive pathology Reference - Endometriosis suspected clinically with negative pathology 1.22 (0.55–2.74) .624 Endometriosis not suspected and not diagnosed 0.47 (0.20–1.10) .081 * Adjusted for race, anxiety, depression ** Adjusted for race, depression *** Adjusted for anxiety **** Adjusted for race\nMultivariable regression analysis of factors associated with use of CBD.\nAdjusted for race, anxiety, depression\nAdjusted for race, depression\nAdjusted for anxiety\nAdjusted for race\n\nCurrently, histopathologic confirmation of endometriosis is required for a definitive diagnosis, but many suggest this requirement is too restrictive, endometriosis diagnosis is shifting from the previously “gold-standard” histological diagnosis to include imaging or clinically based diagnosis  [22] , raising new questions and challenges. Our study, addressing the characteristics and mental health comorbidities of a unique pelvic pain subgroup of clinically suspected endometriosis with negative histopathology (CSENP). These patients without a confirmed diagnosis of endometriosis were in many ways similar to confirmed cases. They had similar body mass indices, similar demographics and similar rates of anxiety. Reported experiences of pain in CSENP patients more closely resembled that of confirmed cases than controls. ESPCN patients also report more frequent use of cannabis for management of pain and anxiety, compared to endometriosis-free matched controls. Compared to endometriosis patients, this group demonstrates increased risk for depression and an increased risk of using cannabis for depression. It is likely that this enhanced risk is underestimated considering the relatively recent legalization of cannabis in California and the remaining stigmatism associated with its use.\nIn our study, endometriosis lesions were not detected in 13% of individuals for whom there was a strong clinical suspicion of endometriosis. The question remains, do the CSENP patients have occult microscopic endometriosis that evaded detection in both surgical and pathologic examinations  [23] ? We have previously shown that in approximately 15% of patients in which endometriosis was not found by histological examination of the first hematoxylin-eosin stained slide, endometriosis lesions were identified if deeper tissue levels were examined histologically  [24] . CSENP could be attributed to either decreased sensitivity of current diagnostic tools or a different, undiagnosed etiology for their pelvic pain. Although answering this question is beyond the scope of our study, the similarities observed between the endometriosis and CSENP groups, together with the absence of an alternative etiology for pain despite comprehensive evaluation, support recognizing CSENP as a distinct clinical entity and reflect a common real-world clinical dilemma. Another theory is discussed in an expert panel called “endometriosis stage 0”, referring to strongly suspected endometriosis based on combinations of symptoms and examination findings in women who either have not undergone surgical diagnosis or with disease visualized but not histologically confirmed  [16] . Our study results of increased comorbid depression in this population could be explained by different race characteristics among groups included in the multivariable analysis. Importantly, while depression proportions did not differ between groups in the univariate analysis, depression became independently associated with CSENP in the multivariable regression analysis.\nRelationships between chronic pelvic pain and depression are bidirectional; chronic pain is broadly associated with worse mental health  [25] , and data from murine models suggest that endometriosis may impact gene expression and function in the brain  [26] . Human studies also report altered brain morphology and connectivity in endometriosis patients compared to controls, with some brain features also associated with severity of anxiety and depression  [27] ,  [28] . A recent study found neurobiological changes in women with endometriosis compared to chronic pelvic pain (CPP) in the absence of endometriosis. Compared to healthy controls, CPP patients have decreased gray matter volume on brain MRI, which in turn correlates with depressive symptoms  [29] , provides plausible biological pathways underlying our observations. Furthermore, increased cerebral blood flow to the medial prefrontal cortex, which plays a central role in pain processing, is associated with pain catastrophizing associated with primary dysmenorrhea  [30] . While we did not survey pain catastrophizing in our study, we did note that CSENP patients were more likely than patients with positive histopathology to undergo hysterectomy, which could reflect a more catastrophic perception of their symptoms resulting in a greater tendency to pursue hysterectomy for definitive management.\nCSENP patients also report more frequent use of cannabis for management of depression as well as for pain and anxiety, compared to endometriosis-free matched controls. Previously published registry data revealed similar rates of cannabis use in both endometriosis and patients with other types of chronic pelvic pain with 15% and 14%, respectively  [15] . Those who used cannabis had higher rates of anxiety, depression, catastrophizing and worse functional quality of life compared with those who were not using cannabis.\nThe main strength of our study is its assessment of endometriosis with pathological and surgical confirmation, which allowed for systematic data collection and reduced recall bias. Moreover, the study utilized a validated and highly granular patient questionnaire, enabling the evaluation of associations for many possible risk factors and more comprehensive adjustment for potential confounders.\nThere are limitations to our study. While there is racial and ethnic diversity in our cohort, it is biased towards patients of European ancestry compared to the general population in the US. Studies involving more diverse populations of endometriosis patients is a critical priority to better understand the distinct clinical challenges for subgroups of patients defined by differing disease presentation  [31] . Additionally, some CSENP patients in our study did report other conditions which may have contributed to their symptoms including painful bladder syndrome and autoimmune conditions. The self-reporting of anxiety and depression is another limitation of the study. While based on objective diagnosis, recall bias could not be excluded. Our data are consistent with large population-based studies demonstrating that endometriosis patients are at significantly increased risk for depressive and anxiety disorders  [32] ,  [33] . We note that rates of anxiety and depression in our endometriosis-free population trended higher than expected in the general population  [32] ,  [34] , potentially due to the high prevalence of fibroids in the ‘No endometriosis’ control group. 47% of the patients in this group underwent myomectomy, and fibroids are also associated with increased risk of anxiety and depression, albeit with more modest hazard ratios than reported for endometriosis  [32] ,  [35] . In addition, as with all observational studies, reverse causation cannot be excluded, as depression and/or anxiety may have led patients to use CBD-containing products. Additionally, we could not rule out the possibility of occult microscopic disease among CSENP patients. Finally, while the multivariable regression analysis accounts for the number of events, the CSENP group size limits the conclusions that can be drawn. Furthermore, we did not collect information on dosage and administration route of CBD and cannabis products, limiting more granular dose-effect analyses. These associations should be considered alongside known risks associated with use of cannabis or CBD-containing products. Chronic users and individuals with a personal or family history of psychiatric conditions are among the most vulnerable to adverse events that include cognitive decline, psychosis and hyperemesis  [36] .\nA growing body of evidence regarding the distinct characteristics of CSENP patients, now underscored by our study findings, suggests this group should be regarded as a distinct subset. Our findings underline high pain levels, increased depression rate and increased use of cannabis for self-treatment in this group. Taken together, these factors place this population at heightened risk for additional comorbidities, increased healthcare utilization, and perpetuated vulnerability. Further research is warranted to better understand the pathophysiology and develop best practice diagnostic and treatment options in this patient population.\n\nRaanan Meyer:  Writing – review & editing, Writing – original draft, Formal analysis, Conceptualization.  Jennifer Sun:  Writing – review & editing, Project administration, Investigation, Data curation.  Christina Lombardi:  Writing – review & editing, Methodology, Investigation, Conceptualization.  Maya Shats:  Writing – review & editing, Investigation.  Pak Hin Yu:  Writing – review & editing, Resources, Data curation.  Forough Abbasi:  Writing – review & editing, Investigation, Data curation.  Ashley Berberian:  Writing – review & editing, Investigation, Data curation.  Anthony Manlinguez:  Writing – review & editing, Investigation, Data curation.  Shruti Kulkarni:  Writing – review & editing, Investigation, Data curation.  Margareta Pisarska:  Writing – review & editing, Investigation.  Fabiola Medeiros:  Writing – review & editing, Investigation, Formal analysis.  Marc T. Goodman:  Writing – review & editing, Writing – original draft, Supervision, Methodology, Funding acquisition, Conceptualization.  Kate Lawrenson:  Writing – review & editing, Writing – original draft, Supervision, Project administration, Investigation, Funding acquisition, Formal analysis, Conceptualization.  Matthew Siedhoff:  Writing – review & editing, Supervision, Funding acquisition.  Kelly N. Wright:  Writing – review & editing, Supervision, Funding acquisition.\n\nThis research is supported in part by grants from the  10.13039/100000002 National Institutes of Health  grant numbers  R01HD114855 ,  R01HD13693  and  R01HG013258 .\n\nNone of the authors have conflicts of interests associated with this project.","source_license":"CC0","license_restricted":false}